• Spyre Therapeutics CEO and director Cameron Turtle sold 14,000 common shares on June 1, 2026.
• Sales were priced at $69.4 to $71.38 per share.
• Post-transaction beneficial ownership stood at 597,540 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000077), on June 03, 2026, and is solely responsible for the information contained therein.